



**IMMUNOLOGY AT THE CONFLUENCE  
OF MULTIDISCIPLINARY  
APPROACHES  
ABSTRACT BOOK**

**Institute for Biological Research "Siniša Stanković" National  
Institute of Republic of Serbia  
University of Belgrade**

**Immunological Society of Serbia**

**IMMUNOLOGY AT THE CONFLUENCE OF  
MULTIDISCIPLINARY APPROACHES**

**ABSTRACT BOOK**

**Hotel Mona Plaza Belgrade**

**December 6<sup>th</sup>-8<sup>th</sup>, 2019**

**Belgrade, 2019**

## **PUBLISHERS**

**Institute for Biological Research "Siniša Stanković" - National Institute of  
Republic of Serbia, University of Belgrade  
Immunological Society of Serbia**

### **For publishers**

**Dr Mirjana Mihailović, director of the Institute for Biological Research "Siniša  
Stanković" - National Institute of Republic of Serbia, University of Belgrade**

**Dr Nada Pejnović, president of the Immunological Society of Serbia**

## **EDITORS**

**Tamara Saksida**

**Suzana Stanisavljević**

**Đorđe Miljković**

**Printed by: Interprint, Kragujevac**

**Circulation: 200**

**ISBN 978-86-80335-12-4**

**This publication is printed by support of the Ministry of Education, Science and  
Technological Development, Republic of Serbia**

## **Congress President**

Nada Pejnović, Immunological Society of Serbia

## **Scientific Committee**

Chairman: Đorđe Miljković, Immunological Society of Serbia

Alisa Gruden-Movsesijan, Immunological Society of Serbia

Biljana Božić-Nedeljković, Faculty of Biology, University of Belgrade

Branka Bonači-Nikolić, Serbian Association of Allergologists and Clinical Immunologists

Branka Vasiljević, Serbian Genetic Society

Gordana Leposavić, Faculty of Pharmacy, University of Belgrade

Gordana Matić, Serbian Society for Molecular Biology

Irena Lavrnja, Serbian Neuroscience Society

Ivan Spasojević, Serbian Biochemical Society

Ivana Mirkov, Immunological Society of Serbia

Ivana Novaković, Serbian Genetic Society

Jelena Drulović, School of Medicine, University of Belgrade

Ljiljana Sofronić-Milosavljević, Institute for Application for Nuclear Energy (INEP), University of Belgrade

Marija Gavrović-Jankulović, Serbian Biochemical Society

Melita Vidaković, Institute for Biological Research „Siniša Stanković“, University of Belgrade

Nevena Arsenović-Ranin, Immunological Society of Serbia

Sanvila Rašković, Serbian Association of Allergologists and Clinical Immunologists

Sladana Andrejević, Serbian Association of Allergologists and Clinical Immunologists

Slavko Mojsilović, Institute for Medical Research (IMI), University of Belgrade

Stanislava Stanojević, Institute of Virology, Vaccines and Sera "Torlak"

Vera Pravica, Immunological Society of Serbia

Vesna Tomić-Spirić, Serbian Association of Allergologists and Clinical Immunologists

Vladimir Jurišić, Faculty of Medical Sciences University of Kragujevac

## **Organizing Committee**

Chairman: Tamara Saksida, Immunological Society of Serbia

Aleksandra Jauković, Institute for Medical Research (IMI), University of Belgrade

Aleksandra Popov Aleksandrov, Immunological Society of Serbia

Ana Đorđević, Serbian Society for Molecular Biology

Biljana Bufan, Faculty of Pharmacy, University of Belgrade

Goran Čuturilo, Serbian Genetic Society

Marijana Stojanović, Institute of Virology, Vaccines and Sera "Torlak"

Nataša Ilić, Institute for Application for Nuclear Energy (INEP), University of Belgrade

Nataša Lončarević-Vasiljković, Serbian Neuroscience Society

Romana Masnikosa, Serbian Biochemical Society

Suzana Stanisavljević, Immunological Society of Serbia

Željka Stanojević, School of Medicine, University of Belgrade

Poster presentation

ETHYL PYRUVATE STIMULATES DIFFERENTIATION OF  
REGULATORY T CELLS *IN VITRO* AND *IN VIVO*

Ivan Koprivica<sup>1</sup>, Dragica Gajić<sup>1</sup>, Nada Pejnović<sup>1</sup>, Tamara Saksida<sup>1</sup>, Ivana  
Stojanović<sup>1</sup>

<sup>1</sup>*Department of Immunology, Institute for Biological Research "Siniša Stanković" - National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia*

Ethyl pyruvate (EP) is a stable form of pyruvate that has shown potent anti-oxidant and anti-inflammatory properties both *in vitro* and *in vivo* and was able to ameliorate systemic inflammation and multiple organ dysfunctions in multiple animal models. Our recent study suggests that the application of EP in the mouse model of type 1 diabetes successfully prevents the clinical manifestation of the disease by augmenting the number of tolerogenic dendritic cells and regulatory T cells (Treg). Our present study indicates that during *in vitro* differentiation of CD4<sup>+</sup> naïve cells into Treg, the addition of EP stimulated Treg generation. This was in line with the observed increased proliferation of newly differentiated Treg (Ki67<sup>+</sup>FoxP3<sup>+</sup>). Surprisingly, EP did not scavenge reactive oxygen species (ROS), but rather stimulated ROS production by Treg. In Treg, ROS is mainly generated during oxidative phosphorylation (OXPHOS) during which the majority of energy for the cell is produced. EP probably acted as a substrate in Krebs cycle because the cells produced more pyruvate dehydrogenase, which converts pyruvate to acetyl CoA. EP treatment also resulted in less kinase of pyruvate dehydrogenase, which acts as an inhibitor of Krebs cycle. As a result, there was an evident stimulation of OXPHOS, confirmed by increased ATP production in differentiated Treg. Additionally, EP exerted its stimulatory function on Treg in healthy C57BL/6 mice. When given either intraperitoneally or *per os*, EP increased Treg numbers within the peritoneal cavity or gut-associated lymphoid tissue, respectively. Seemingly, EP promoted differentiation of Treg *in vivo* and did not affect their suppressive properties (proportion of CTLA-4<sup>+</sup>, CD39<sup>+</sup>, PD-1<sup>+</sup>, IL-10<sup>+</sup> Treg) or their affinity towards specific effector T helper cells (RORγT<sup>+</sup>, Tbet<sup>+</sup> or GATA-3<sup>+</sup> Treg). In conclusion, EP acts as specific metabolic fuel for Treg generation, likely because these cells mainly rely on OXPHOS-derived energy